|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Iowa Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing IowaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
KemPharm, Inc
| | | Phone: | (319) 665-2575 | Fax: | (319) 665-2577 | Year Established: | 2006 | Ticker: | KMPH | Exchange: | NASDAQ | Main Contact: | Gordon Johnson, CBO | | Other Contacts: | Rene A. Braeckman, Ph.D., VP, Clinical Development Daniel L. Cohen, Executive VP, Government & Public Relations Andrew Barrett, Ph.D., VP, Scientific Affairs Christopher M. Lauderback, VP, Commercial Operations Sven Guenther, Ph.D., Executive VP, Research Travis C. Mickle, Ph.D., CEO, Chairman & Co-Founder
| | Company Description | KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders. | |
|
|
|
|
|